Gay Men Turn to 19 Black-Market Peptides for Muscle Growth Despite Safety Risks
Updated
Updated · Out Magazine · Jun 30
Gay Men Turn to 19 Black-Market Peptides for Muscle Growth Despite Safety Risks
3 articles · Updated · Out Magazine · Jun 30
Summary
Black-market injectable peptides are gaining traction among gay men seeking lean muscle, faster recovery and a more youthful look, even though the products are not FDA-approved.
Pressure from toxic gym culture, circuit-party aesthetics and fatphobia on hookup apps helps drive that demand; one study cited found disordered-eating symptoms were 10 times higher in gay and bisexual men than in heterosexual men.
Doctors say users are often drawn by claims that peptides offer softer side effects than steroids, but evidence for many bodybuilding peptides remains thin and the hype is outpacing proven results.
Nineteen peptides had their regulatory status tightened by the Biden-era FDA, pushing some buyers toward underground channels such as Discord, Telegram and direct orders from Chinese manufacturers.
Experts warn the biggest dangers are contamination, mislabeling and hormone disruption, alongside side effects including water retention, numbness, blood-sugar changes and injection-related infection.
Are users injecting a fountain of youth or a cocktail of unstudied, life-threatening risks?
Will relaxing peptide laws crush the black market or unleash a new health crisis?
FDA’s 2026 Peptide Rulings: How Regulatory Uncertainty Fuels Black Market Growth and Patient Risk
Overview
In July 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) is meeting to review the status of several peptides, with a final decision on seven specific compounds expected soon. This review is crucial, as it will determine whether these peptides can continue to be compounded, directly affecting patient access and the operations of compounding pharmacies across the country. The FDA panel is evaluating evidence for using these peptides in conditions like ulcerative colitis, wound healing, obesity, and migraines. The outcome will significantly shape the future regulation and availability of peptide therapies in the United States.